Clinical Trial Update: Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression [Phase 3]

View source ↗

Summary

Clinical trial update evaluating switching from protease inhibitor to etravirine in HIV-1 infected subjects with suppressed viremia (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• etravirine (etravirine)

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: HIV | Phase 3 | Status: COMPLETED